<DOC>
	<DOCNO>NCT02170701</DOCNO>
	<brief_summary>- To determine therapeutic window BIBR 1048 order select dose study development plan . - Twice daily regimen test dose level daily administration also evaluate appropriate .</brief_summary>
	<brief_title>BIBR 1048 Prevention Venous Thromboembolism Patients Undergoing Primary Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patients schedule undergo primary elective total hip replacement Male female 18 year old Patients weigh least 40 kg Written inform consent study participation Bleeding diathesis , constitutional acquire coagulation disorder Major surgery trauma ( e.g . hip fracture ) within last three month . Patients previous hip fracture associate plate revision time exclude Cardiovascular disease include uncontrolled hypertension time enrolment history myocardial infarction within last 6 month Any history haemorrhagic stroke , intracranial intraocular bleed cerebral ischaemic attack Known history deep venous thrombosis ( DVT ) Gastrointestinal pulmonary bleeding within last year Known liver disease Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 3 x ULN ) Known renal disease ( serum creatinine &gt; 1.5 x ULN ) Use long term anticoagulant , antiplatelet drug , fibrinolytics within 7 day prior hip replacement operation ( also contraindicate period prophylaxis ) Women childbearing potential Known allergy radiopaque contrast medium Known thrombocytopenia ( prior platelet count 100,000 cells/microliter ) Active malignant disease Current H2 blocker proton pump inhibitor treatment Current cytostatic treatment Treatment investigational drug past month Leg amputee Known alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>